Skip to content

Bioventus BVS Finished goods

Finished goods at other companies

Artivion logo
ArtivionAORT
$39.7M+27.4%
Enovis logo
EnovisENOV
$512M-1.5%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$222.3M+11.9%
IAR
Integra LifeSciencesIART
$253.15M+12.3%
Medtronic logo
MedtronicMDT
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's finished goods?
Bioventus (BVS) reported finished goods of $63.89M in Q1 2026.
How has Bioventus's finished goods changed year-over-year?
Bioventus's finished goods decreased by 10.3% year-over-year, from $71.2M to $63.89M.
What is the long-term trend for Bioventus's finished goods?
Over 5 years (2020 to 2025), Bioventus's finished goods has grown at a 18.3% compound annual growth rate (CAGR), from $26.32M to $61M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.